An LSD Pill Just Crushed Every Depression Drug in a Phase 3 Trial

The response and remission numbers tell a similar story. At Week 6, 35% of DT120 patients had their symptoms cut in half (the standard definition of "response"), compared to just 7% on placebo. Remission rates were 24% versus 3%. Those gaps are enormous by psychiatric drug standards.

One Dose, No Therapy Required

Here's what makes DT120 particularly interesting from a practical standpoint: it doesn't require psychotherapy bolted on. Many psychedelic treatment models (think psilocybin-assisted therapy) involve lengthy guided sessions with trained therapists before, during, and after the drug experience. That's expensive, hard to scale, and creates a bottleneck.

Definium designed its trials around DT120 as a standalone drug. Patients took the tablet in a supervised clinic setting and were monitored for about 5 to 8 hours while the transient psychedelic-like effects wore off. No mandated therapy sessions. No multi-day protocols. That's a much cleaner model for real-world psychiatry, closer to how Spravato clinics already operate.

On safety, the results were equally clean. 99% of side effects were mild to moderate, mostly occurring on dosing day and resolving quickly. There were no serious adverse events and no signals of increased suicidality, which is always the critical safety question in depression trials.

The Competitive Landscape Just Got Interesting

Psilocybin has long been considered the frontrunner in psychedelic psychiatry. Compass Pathways has a Phase 3 program targeting treatment-resistant depression. But none of the psilocybin developers have posted Phase 3 numbers like these yet.

Definium (formerly known as MindMed) rebranded in January 2026 and now trades under the ticker DFTX. The company already holds FDA Breakthrough Therapy Designation for DT120 in generalized anxiety disorder, and it has a second pivotal MDD trial called Ascend actively enrolling. The stock jumped roughly 39 to 60% intraday after the data dropped, hitting all-time highs.

Analyst François Brisebois raised his price target to $44, and multiple firms reaffirmed Buy ratings. The consensus view: Emerge is a major de-risking event. Definium is sitting on about $373.4 million in cash as of its most recent quarterly report, enough to fund the remaining trials, prepare an NDA filing, and start building out commercial infrastructure without tapping the market for more money.

What Still Needs to Happen

Before anyone gets too euphoric (pun intended), there are real hurdles left.

First, the FDA typically wants two pivotal trials for a new drug approval. Emerge is one. Ascend needs to replicate these results. If the second study comes back weaker or inconsistent, the whole narrative shifts.

Second, this is an LSD-derived compound. It will almost certainly require a REMS program (basically, a set of safety guardrails the FDA imposes on risky drugs). Think: certified clinics, trained staff, mandatory monitoring periods. Definium says it's already in active dialogue with the FDA on exactly what that framework will look like.

Third, durability beyond 12 weeks remains an open question. The Emerge data is encouraging through three months, but regulators and payers will want to understand what happens when patients relapse. How often can you re-dose? What does the long-term safety profile look like? The 40-week open-label extension of Emerge should provide some of those answers.

Finally, there's the broader policy environment. Psychedelics remain Schedule I substances in the United States. Even with strong clinical data, the path from FDA approval to rescheduling to widespread insurance coverage involves navigating political, regulatory, and cultural headwinds that no amount of p-values can fully resolve.

The Bottom Line

Depression affects over 280 million people worldwide, and the current standard of care (daily pills that take weeks to maybe work, with effect sizes barely above placebo) has been essentially unchanged for decades. Esketamine nudged the field forward. Psilocybin has generated enormous excitement.

But DT120 just walked into the room with the kind of Phase 3 data that makes drug developers, investors, and (most importantly) patients sit up. A single dose. Rapid onset. Durable effect. A clean safety profile. No mandatory therapy.

If Ascend confirms what Emerge just showed, Definium won't just have a promising drug on its hands. It'll have a genuine paradigm shift.

The FDA Just Gave Itself a Live Feed Into Clinical Trials

The FDA is getting a live data feed from two oncology trials run by AstraZeneca and Amgen, ditching the decades-old model of waiting months between data checkpoints. If it works, drug development timelines could shrink by years.